AspenBio Pharma up on agreement with Novartis Animal Health
Shares of AspenBio Pharma, Inc. (Nasdaq:APPY) are advancing ahead of the bell after the bio-pharmaceutical company said this morning that it secured a long-term exclusive license and commercialization agreement with Novartis Animal Health, Inc. to develop its recombinant single-chain bovine products, BoviPure LH and BoviPure FSH.
Shares gained 12.3%, or $0.74, to $6.74 in ahead of the opening bell. For detailed price information and recent news stories about AspenBio Pharma, click APPY.
